Advances in the Management of Severe Asthma

Salman Siddiqui; Sherif Gonem; Andrew J. Wardlaw

doi:10.1055/s-0032-1326964

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2012; 33(06): 666-684
DOI: 10.1055/s-0032-1326964

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Advances in the Management of Severe Asthma

Salman Siddiqui

¹Department of Infection, Immunity, and Inflammation, Institute for Lung Health, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester, United Kingdom

,

Sherif Gonem

¹Department of Infection, Immunity, and Inflammation, Institute for Lung Health, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester, United Kingdom

,

Andrew J. Wardlaw

¹Department of Infection, Immunity, and Inflammation, Institute for Lung Health, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester, United Kingdom

› Institutsangaben

Abstract

Severe asthma affects 5 to 10% of the asthma population but consumes a disproportionate amount of the global asthma budget (∼50%) due to unscheduled health care utilization in primary care, hospitalizations due to severe exacerbations, and the costs of pharmacotherapy. A key challenge in managing severe asthma is to identify appropriate groups of patients that will respond best to existing and evolving therapies. Recent advances in our understanding of how to classify severe asthma using multivariate taxonomical approaches have provided a unique model of a stratified medicines approach. For example, patients with inflammation-predominant asthma with eosinophils benefit from both inhaled and oral corticosteroids as well as targeted biologics such as anti-interleukin (IL)-5, all of which significantly reduce asthma exacerbations. On the other hand, patients with noneosinophilic neutrophilic asthma may be more suitable for steroid down-titration and therapeutic trials of antineutrophilic agents such as macrolide antibiotics. A similar paradigm can be applied to other domains in severe asthma such as airway hyperresponsiveness, which may now be treated with the first mechanical therapy in airways disease (bronchial thermoplasty). At the same time it is important for the clinician to recognize and treat comorbid factors that make asthma difficult to manage such as poor adherence to medication, rhinosinusitis, and psychological comorbidity. Therefore it is of vital importance to develop a multidisciplinary approach to the management of severe asthma that is best applied within specialist centers with experience and wider access to national and international severe asthma networks.

Keywords

severe asthma - personalized medicine - biomarkers - phenotypes

Volltext

Referenzen

References
1 Masoli M, Fabian D, Holt S, Beasley R ; Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59 (5) 469-478
2 Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med 2005; 172 (2) 149-160
3 Chanez P, Wenzel SE, Anderson GP , et al. Severe asthma in adults: what are the important questions?. J Allergy Clin Immunol 2007; 119 (6) 1337-1348
4 Moore WC, Bleecker ER, Curran-Everett D , et al; National Heart, Lung, Blood Institute's Severe Asthma Research Program. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119 (2) 405-413
5 Bousquet J, Mantzouranis E, Cruz AA , et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010; 126 (5) 926-938
6 Chung KF, Godard P, Adelroth E , et al; European Respiratory Society. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. Eur Respir J 1999; 13 (5) 1198-1208
7 American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000; 162 (6) 2341-2351
8 Global Initiative for Asthma Guidelines. 2008. Global strategy for asthma management and prevention. http://www ginasthma com . Accessed January 7, 2008
9 Chanez P, Wenzel SE, Anderson GP , et al. Severe asthma in adults: what are the important questions?. J Allergy Clin Immunol 2007; 119 (6) 1337-1348
10 Nathan RA, Sorkness CA, Kosinski M , et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113 (1) 59-65
11 Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14 (4) 902-907
12 Peters D, Chen C, Markson LE, Allen-Ramey FC, Vollmer WM. Using an asthma control questionnaire and administrative data to predict health-care utilization. Chest 2006; 129 (4) 918-924
13 Thomas M, Gruffydd-Jones K, Stonham C, Ward S, Macfarlane TV. Assessing asthma control in routine clinical practice: use of the Royal College of Physicians ‘3 questions’. Prim Care Respir J 2009; 18 (2) 83-88
14 LeBlanc A, Robichaud P, Lacasse Y, Boulet LP. Quantification of asthma control: validation of the Asthma Control Scoring System. Allergy 2007; 62 (2) 120-125
15 Miller MK, Johnson C, Miller DP, Deniz Y, Bleecker ER, Wenzel SE ; TENOR Study Group. Severity assessment in asthma: An evolving concept. J Allergy Clin Immunol 2005; 116 (5) 990-995
16 Dolan CM, Fraher KE, Bleecker ER , et al; TENOR Study Group. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004; 92 (1) 32-39
17 European Network for Understanding Mechanisms of Severe Asthma. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003; 22 (3) 470-477
18 Cowburn AS, Sladek K, Soja J , et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998; 101 (4) 834-846
19 Heaney LG, Brightling CE, Menzies-Gow A, Stevenson M, Niven RM ; British Thoracic Society Difficult Asthma Network. Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. Thorax 2010; 65 (9) 787-794
20 Wardlaw AJ, Silverman M, Siva R, Pavord ID, Green R. Multi-dimensional phenotyping: towards a new taxonomy for airway disease. Clin Exp Allergy 2005; 35 (10) 1254-1262
21 Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008; 372 (9643) 1107-1119
22 Lötvall J, Akdis CA, Bacharier LB , et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011; 127 (2) 355-360
23 Haldar P, Pavord ID, Shaw DE , et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178 (3) 218-224
24 Haldar P, Brightling CE, Hargadon B , et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360 (10) 973-984
25 Green RH, Brightling CE, McKenna S , et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360 (9347) 1715-1721
26 Woodruff PG, Modrek B, Choy DF , et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180 (5) 388-395
27 Moore WC, Meyers DA, Wenzel SE , et al; National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181 (4) 315-323
28 Hargreave FE, Nair P. The definition and diagnosis of asthma. Clin Exp Allergy 2009; 39 (11) 1652-1658
29 Pavord ID, Wardlaw AJ. The A to E of airway disease. Clin Exp Allergy 2010; 40 (1) 62-67
30 Sin DD, Man J, Sharpe H, Gan WQ, Man SF. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA 2004; 292 (3) 367-376
31 Bateman ED, Boushey HA, Bousquet J , et al; GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170 (8) 836-844
32 Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM ; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129 (1) 15-26
33 Weatherall M, Wijesinghe M, Perrin K, Harwood M, Beasley R. Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Thorax 2010; 65 (1) 39-43
34 US Food and Drug Administration. Long-Acting Beta-Agonists (LABAs): New Safe Use Requirements. Silver Spring, MD: FDA; 2011. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm201003.htm . Accessed October 22, 2010
35 van Noord JA, Smeets JJ, Raaijmakers JA, Bommer AM, Maesen FP. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996; 9 (8) 1684-1688
36 Baraniuk JN, Ali M, Brody D , et al. Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med 1997; 155 (2) 704-710
37 Bateman ED, Harrison TW, Quirce S , et al. Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respir Res 2011; 12: 38
38 Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet 2001; 357 (9273) 2007-2011
39 Storms W, Michele TM, Knorr B , et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years. Clin Exp Allergy 2001; 31 (1) 77-87
40 Micheletto C, Visconti M, Tognella S, Facchini FM, Dal Negro RW. Aspirin induced asthma (AIA) with nasal polyps has the highest basal LTE4 excretion: a study vs AIA without polyps, mild topic asthma, and normal controls. Eur Ann Allergy Clin Immunol 2006; 38 (1) 20-23
41 Barnes PJ. Histone deacetylase-2 and airway disease. Ther Adv Respir Dis 2009; 3 (5) 235-243
42 Westby M, Benson M, Gibson P. Anticholinergic agents for chronic asthma in adults. Cochrane Database Syst Rev 2004; (3) CD003269
43 Peters SP, Kunselman SJ, Icitovic N , et al; National Heart, Lung, and Blood Institute Asthma Clinical Research Network. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010; 363 (18) 1715-1726
44 Kerstjens HA, Disse B, Schröder-Babo W , et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol 2011; 128 (2) 308-314
45 Pavord ID, Pizzichini MM, Pizzichini E, Hargreave FE. The use of induced sputum to investigate airway inflammation. Thorax 1997; 52 (6) 498-501
46 Pizzichini E, Pizzichini MM, Leigh R, Djukanović R, Sterk PJ. Safety of sputum induction. Eur Respir J Suppl 2002; 37: 9s-18s
47 Efthimiadis A, Spanevello A, Hamid Q , et al. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. Eur Respir J Suppl 2002; 37: 19s-23s
48 Keatings VM, Evans DJ, O'Connor BJ, Barnes PJ. Cellular profiles in asthmatic airways: a comparison of induced sputum, bronchial washings, and bronchoalveolar lavage fluid. Thorax 1997; 52 (4) 372-374
49 Pizzichini E, Pizzichini MM, Kidney JC , et al. Induced sputum, bronchoalveolar lavage and blood from mild asthmatics: inflammatory cells, lymphocyte subsets and soluble markers compared. Eur Respir J 1998; 11 (4) 828-834
50 Keatings VM, Evans DJ, O'Connor BJ, Barnes PJ. Cellular profiles in asthmatic airways: a comparison of induced sputum, bronchial washings, and bronchoalveolar lavage fluid. Thorax 1997; 52 (4) 372-374
51 Meijer RJ, Postma DS, Kauffman HF, Arends LR, Koëter GH, Kerstjens HA. Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma. Clin Exp Allergy 2002; 32 (7) 1096-1103
52 Little SA, Chalmers GW, MacLeod KJ, McSharry C, Thomson NC. Non-invasive markers of airway inflammation as predictors of oral steroid responsiveness in asthma. Thorax 2000; 55 (3) 232-234
53 Meijer RJ, Postma DS, Kauffman HF, Arends LR, Koëter GH, Kerstjens HA. Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma. Clin Exp Allergy 2002; 32 (7) 1096-1103
54 Leuppi JD, Salome CM, Jenkins CR , et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001; 163 (2) 406-412
55 Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000; 161 (1) 64-72
56 Jayaram L, Pizzichini MM, Cook RJ , et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27 (3) 483-494
57 Chlumský J, Striz I, Terl M, Vondracek J. Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma. J Int Med Res 2006; 34 (2) 129-139
58 Petsky HL, Cates CJ, Lasserson TJ , et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012; 67 (3) 199-208
59 Flood-Page P, Swenson C, Faiferman I , et al; International Mepolizumab Study Group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176 (11) 1062-1071
60 Nair P, Pizzichini MM, Kjarsgaard M , et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360 (10) 985-993
61 Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev 2000; (2) CD000391
62 Shiner RJ, Nunn AJ, Chung KF, Geddes DM. Randomised, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet 1990; 336 (8708) 137-140
63 Domingo C, Moreno A, Amengual MJ, Comet R, Luján M. Twelve years' experience with methotrexate for GINA treatment step 5 asthma patients. Curr Med Res Opin 2009; 25 (2) 367-374
64 Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma : evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001; 119 (5) 1329-1336
65 Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57 (10) 875-879
66 Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999; 160 (5 Pt 1) 1532-1539
67 Chalmers GW, MacLeod KJ, Thomson L, Little SA, McSharry C, Thomson NC. Smoking and airway inflammation in patients with mild asthma. Chest 2001; 120 (6) 1917-1922
68 Shaw DE, Berry MA, Hargadon B , et al. Association between neutrophilic airway inflammation and airflow limitation in adults with asthma. Chest 2007; 132 (6) 1871-1875
69 Busacker A, Newell Jr JD, Keefe T , et al. A multivariate analysis of risk factors for the air-trapping asthmatic phenotype as measured by quantitative CT analysis. Chest 2009; 135 (1) 48-56
70 Scott HA, Gibson PG, Garg ML, Wood LG. Airway inflammation is augmented by obesity and fatty acids in asthma. Eur Respir J 2011; 38 (3) 594-602
71 Cowan DC, Cowan JO, Palmay R, Williamson A, Taylor DR. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax 2010; 65 (5) 384-390
72 Simpson JL, Grissell TV, Douwes J, Scott RJ, Boyle MJ, Gibson PG. Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax 2007; 62 (3) 211-218
73 Crosbie PA, Woodhead MA. Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 2009; 33 (1) 171-181
74 Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008; 177 (2) 148-155
75 Rosenstreich DL, Eggleston P, Kattan M , et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. N Engl J Med 1997; 336 (19) 1356-1363
76 O'Hollaren MT, Yunginger JW, Offord KP , et al. Exposure to an aeroallergen as a possible precipitating factor in respiratory arrest in young patients with asthma. N Engl J Med 1991; 324 (6) 359-363
77 Targonski PV, Persky VW, Ramekrishnan V. Effect of environmental molds on risk of death from asthma during the pollen season. J Allergy Clin Immunol 1995; 95 (5 Pt 1) 955-961
78 Black PN, Udy AA, Brodie SM. Sensitivity to fungal allergens is a risk factor for life-threatening asthma. Allergy 2000; 55 (5) 501-504
79 Bush RK, Swenson C, Fahlberg B , et al. House dust mite sublingual immunotherapy: results of a US trial. J Allergy Clin Immunol 2011; 127 (4) 974-981 , e1–e7
80 Humbert M, Beasley R, Ayres J , et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60 (3) 309-316
81 Busse WW, Massanari M, Kianifard F, Geba GP. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis. Curr Med Res Opin 2007; 23 (10) 2379-2386
82 O'Driscoll BR, Powell G, Chew F , et al. Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma. Clin Exp Allergy 2009; 39 (11) 1677-1683
83 Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002; 110 (5) 685-692
84 Fairs A, Wardlaw AJ, , Thompson Jr, Pashley CH. Guidelines on ambient intramural airborne fungal spores. J Investig Allergol Clin Immunol 2010; 20 (6) 490-498
85 Fairs A, Agbetile J, Hargadon B , et al. IgE sensitization to Aspergillus fumigatus is associated with reduced lung function in asthma. Am J Respir Crit Care Med 2010; 182 (11) 1362-1368
86 Denning DW, O'Driscoll BR, Hogaboam CM, Bowyer P, Niven RM. The link between fungi and severe asthma: a summary of the evidence. Eur Respir J 2006; 27 (3) 615-626
87 Denning DW, O'Driscoll BR, Powell G , et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009; 179 (1) 11-18
88 Wark PA, Gibson PG, Wilson AJ. Azoles for allergic bronchopulmonary aspergillosis associated with asthma. Cochrane Database Syst Rev 2004; (3) CD001108
89 Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ ; The AMPUL Study Group. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Respir Crit Care Med 1999; 159 (4 Pt 1) 1043-1051
90 Danek CJ, Lombard CM, Dungworth DL , et al. Reduction in airway hyperresponsiveness to methacholine by the application of RF energy in dogs. J Appl Physiol 2004; 97 (5) 1946-1953
91 Miller JD, Cox G, Vincic L, Lombard CM, Loomas BE, Danek CJ. A prospective feasibility study of bronchial thermoplasty in the human airway. Chest 2005; 127 (6) 1999-2006
92 Pavord ID, Cox G, Thomson NC , et al; RISA Trial Study Group. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med 2007; 176 (12) 1185-1191
93 Castro M, Rubin AS, Laviolette M , et al; AIR2 Trial Study Group. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010; 181 (2) 116-124
94 Siddiqui S, Mistry V, Doe C , et al. Airway hyperresponsiveness is dissociated from airway wall structural remodeling. J Allergy Clin Immunol 2008; 122 (2) 335-341 , 341, e1–e3
95 Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002; 346 (22) 1699-1705
96 Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol 2008; 121 (1) 5-10 , quiz 11–12
97 Berry MA, Hargadon B, Shelley M , et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006; 354 (7) 697-708
98 Wenzel SE, Barnes PJ, Bleecker ER , et al; T03 Asthma Investigators. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009; 179 (7) 549-558
99 Saha SK, Berry MA, Parker D , et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol 2008; 121 (3) 685-691
100 Taube C, Wei X, Swasey CH , et al. Mast cells, Fc epsilon RI, and IL-13 are required for development of airway hyperresponsiveness after aerosolized allergen exposure in the absence of adjuvant. J Immunol 2004; 172 (10) 6398-6406
101 Corren J, Busse W, Meltzer EO , et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010; 181 (8) 788-796
102 Gupta S, Siddiqui S, Haldar P , et al. Qualitative analysis of high-resolution CT scans in severe asthma. Chest 2009; 136 (6) 1521-1528
103 Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002; 110 (5) 685-692
104 Aysola RS, Hoffman EA, Gierada D , et al. Airway remodeling measured by multidetector CT is increased in severe asthma and correlates with pathology. Chest 2008; 134 (6) 1183-1191
105 Siddiqui S, Gupta S, Cruse G , et al. Airway wall geometry in asthma and nonasthmatic eosinophilic bronchitis. Allergy 2009; 64 (6) 951-958
106 Gupta S, Siddiqui S, Haldar P , et al. Quantitative analysis of high-resolution computed tomography scans in severe asthma subphenotypes. Thorax 2010; 65 (9) 775-781
107 Mastronarde JG, Anthonisen NR, Castro M , et al; American Lung Association Asthma Clinical Research Centers. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med 2009; 360 (15) 1487-1499
108 Kiljander TO, Junghard O, Beckman O, Lind T. Effect of esomeprazole 40 mg once or twice daily on asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2010; 181 (10) 1042-1048
109 Kiljander TO, Harding SM, Field SK , et al. Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2006; 173 (10) 1091-1097
110 Stelmach R, do Patrocínio T Nunes M, Ribeiro M, Cukier A. Effect of treating allergic rhinitis with corticosteroids in patients with mild-to-moderate persistent asthma. Chest 2005; 128 (5) 3140-3147
111 Sin DD, Sutherland ER. Obesity and the lung, IV: Obesity and asthma. Thorax 2008; 63 (11) 1018-1023
112 Julien JY, Martin JG, Ernst P , et al. Prevalence of obstructive sleep apnea-hypopnea in severe versus moderate asthma. J Allergy Clin Immunol 2009; 124 (2) 371-376
113 Eneli IU, Skybo T, Camargo Jr CA. Weight loss and asthma: a systematic review. Thorax 2008; 63 (8) 671-676
114 Thomas M, McKinley RK, Freeman E, Foy C. Prevalence of dysfunctional breathing in patients treated for asthma in primary care: cross sectional survey. BMJ 2001; 322 (7294) 1098-1100
115 Thomas M, McKinley RK, Freeman E, Foy C, Price D. The prevalence of dysfunctional breathing in adults in the community with and without asthma. Prim Care Respir J 2005; 14 (2) 78-82
116 Thomas M, McKinley RK, Mellor S , et al. Breathing exercises for asthma: a randomised controlled trial. Thorax 2009; 64 (1) 55-61
117 Alvarez GG, Fitzgerald JM. A systematic review of the psychological risk factors associated with near fatal asthma or fatal asthma. Respiration 2007; 74 (2) 228-236
118 Heaney LG, Conway E, Kelly C, Gamble J. Prevalence of psychiatric morbidity in a difficult asthma population: relationship to asthma outcome. Respir Med 2005; 99 (9) 1152-1159
119 Fagan J, Galea S, Ahern J, Bonner S, Vlahov D. Relationship of self-reported asthma severity and urgent health care utilization to psychological sequelae of the September 11, 2001 terrorist attacks on the World Trade Center among New York City area residents. Psychosom Med 2003; 65 (6) 993-996
120 Brown ES, Khan DA, Mahadi S. Psychiatric diagnoses in inner city outpatients with moderate to severe asthma. Int J Psychiatry Med 2000; 30 (4) 319-327
121 Valença AM, Falcão R, Freire RC , et al. The relationship between the severity of asthma and comorbidities with anxiety and depressive disorders. Rev Bras Psiquiatr 2006; 28 (3) 206-208
122 Smith JR, Mugford M, Holland R, Noble MJ, Harrison BD. Psycho-educational interventions for adults with severe or difficult asthma: a systematic review. J Asthma 2007; 44 (3) 219-241
123 Gamble J, Stevenson M, McClean E, Heaney LG. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009; 180 (9) 817-822
124 Cohen JL, Mann DM, Wisnivesky JP , et al. Assessing the validity of self-reported medication adherence among inner-city asthmatic adults: the Medication Adherence Report Scale for Asthma. Ann Allergy Asthma Immunol 2009; 103 (4) 325-331
125 Haupt D, Nilsson JL. Asthma medication - persistence with adrenergics, steroids and combination products over a 5-year period. J Clin Pharm Ther 2009; 34 (5) 507-513
126 Bae YJ, Kim TB, Jee YK , et al. Severe asthma patients in Korea overestimate their adherence to inhaled corticosteroids. J Asthma 2009; 46 (6) 591-595
127 Ponieman D, Wisnivesky JP, Leventhal H, Musumeci-Szabó TJ, Halm EA. Impact of positive and negative beliefs about inhaled corticosteroids on adherence in inner-city asthmatic patients. Ann Allergy Asthma Immunol 2009; 103 (1) 38-42
128 Janson SL, McGrath KW, Covington JK, Cheng SC, Boushey HA. Individualized asthma self-management improves medication adherence and markers of asthma control. J Allergy Clin Immunol 2009; 123 (4) 840-846
129 Strandbygaard U, Thomsen SF, Backer V. A daily SMS reminder increases adherence to asthma treatment: a three-month follow-up study. Respir Med 2010; 104 (2) 166-171
130 Breekveldt-Postma NS, Gerrits CM, Lammers JW, Raaijmakers JA, Herings RM. Persistence with inhaled corticosteroid therapy in daily practice. Respir Med 2004; 98 (8) 752-759
131 Breekveldt-Postma NS, Koerselman J, Erkens JA, van der Molen T, Lammers JW, Herings RM. Treatment with inhaled corticosteroids in asthma is too often discontinued. Pharmacoepidemiol Drug Saf 2008; 17 (4) 411-422
132 Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343 (5) 332-336
133 Lehane E, McCarthy G. An examination of the intentional and unintentional aspects of medication non-adherence in patients diagnosed with hypertension. J Clin Nurs 2007; 16 (4) 698-706
134 ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. “Refractory” eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med 2004; 170 (6) 601-605